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2Shortened abstract for graphical table of contents
Mephedrone users often employ repeated administration due to its short duration of action.
This study investigated the role of dopamine and 5-HT in mephedrone-induced hyperactivity
and hypothermia following repeated administration. Mephedrone increased striatal dopamine
and 5-HT release following each injection. Mephedrone-induced hyperactivity and
hypothermia were attenuated by 5-HT depletion, and by 5-HT1B or 5-HT1A receptor
antagonism, respectively. These findings suggest that stimulation of central 5-HT release
and/or inhibition of 5-HT reuptake plays a pivotal role in mephedrone-induced hyperactivity
and hypothermia.
3Abstract
The psychoactive effects of mephedrone are commonly compared to those of 3,4-
methylenedioxymethamphetamine, but because of a shorter duration of action users often
employ repeated administration to maintain its psychoactive actions. This study examined the
effects of repeated mephedrone administration on locomotor activity, body temperature and
striatal dopamine and 5-hydroxytryptamine (5-HT) levels, and the role of dopaminergic and
serotonergic neurons in these responses. Adult male Lister hooded rats received three
injections of vehicle (1ml/kg, i.p.) or mephedrone HCl (10mg/kg) at 2h intervals for
radiotelemetry (temperature and activity) or microdialysis (dopamine and 5-HT)
measurements. Intracerebroventricular pre-treatment (21 to 28 days earlier) with 5,7-
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to examine the impact of 5-HT or dopamine depletion on mephedrone-induced changes in
temperature and activity. A final study examined the influence of i.p. pre-treatment (-30min)
with the 5-HT1A receptor antagonist WAY-100635 (0.5mg/kg), 5-HT1B receptor antagonist
GR 127935 (3mg/kg) or the 5-HT7 receptor antagonist SB-258719 (10mg/kg) on
mephedrone-induced changes in locomotor activity and rectal temperature. Mephedrone
caused rapid-onset hyperactivity, hypothermia (attenuated on repeat dosing), and increased
striatal dopamine and 5-HT release following each injection. Mephedrone-induced
hyperactivity was attenuated by 5-HT depletion and 5-HT1B receptor antagonism, whereas the
hypothermia was completely abolished by 5-HT depletion and lessened by 5-HT1A receptor
antagonism. These findings suggest that stimulation of central 5-HT release and/or inhibition
of 5-HT reuptake play a pivotal role in both the hyperlocomotor and hypothermic effects of
mephedrone, which are mediated in part via 5-HT1B and 5-HT1A receptors.
Keywords: 5-HT, dopamine, locomotor activity, mephedrone, microdialysis, telemetry
4Introduction
The synthetic cathinone derivative 4-methylmethcathinone (mephedrone) was first
synthesized in 1929 and became popular amongst recreational users at the beginning of the
21
st
century as a legal high (Green et al., 2014). Although mephedrone has been implicated in
a number of deaths and became illegal in Europe and the United States between 2010 and
2012 (Dargan et al., 2011; Gershman and Fass, 2012), it remains widely available for illicit
use (Elliott and Evans, 2014; Kelly et al., 2013; Yamamoto et al., 2013) and users report
similar psychoactive effects to 3,4-methylenedioxymethamphetamine (MDMA). Mephedrone
is a high-affinity substrate for the monoamine reuptake transporters for dopamine,
noradrenaline and 5-hydroxytrypatamine (5-HT). Once transported into the cell mephedrone
stimulates neurotransmitter release and disrupts vesicular storage by interaction with the
vesicular monoamine transporter (VMAT) and can also stimulate non-exocytotic release by
reversing the monoamine transporter flux (Simmler et al., 2013). Consistent with this,
systemic mephedrone administration to freely moving rats elevates extracellular levels of
dopamine, and to a greater extent 5-HT, in the nucleus accumbens (Baumann et al., 2012;
Kehr et al., 2011; Wright et al., 2012).
Multiple re-dosing is common with mephedrone users attempting to maintain the
desired effects of this short-acting drug, and while a typical recreational dose is often
between 100-200mg, individuals may re-dose and ingest up to 4g in a single session
(Schifano et al., 2011; Winstock et al., 2011). Most studies show the acute effect of a single
injection, or self-administration of mephedrone in the rat is hypothermia (Aarde et al., 2013;
Miller et al., 2013; Shortall et al., 2013a), but hyperthermia has also been reported following
rapid repeated dosing (Baumann et al, 2012; Hadlock et al, 2011). Given the established
association of hyperthermia with life-threatening adverse effects of MDMA (Docherty and
Green, 2010), it is essential to see if there might be a similar adverse risk with repeated
5mephedrone. The current study therefore examined the temporal profile of the temperature
and locomotor response to short-term repeated mephedrone and established the involvement
of serotonergic and dopaminergic neurons in these changes because of their known role in the
effects of MDMA.
In the current study rats received three intraperitoneal (i.p.) injections of mephedrone
(10mg/kg) at 2h intervals. Previous calculations suggest that this dose and route of
mephedrone administration would produce similar plasma exposure to that occurring in many
recreational users (Green et al., 2014). However, as pharmacokinetic studies of mephedrone
have not been performed in man and there is wide variation in use of single or repeated
recreational dose schedules, firm conclusions of the translatable accuracy of this dose cannot
be made. Importantly, 10mg/kg i.p. produces robust but sub-maximal physiological and
behavioral changes in the rat (Shortall et al., 2013a; Shortall et al., 2013b; Wright et al.,
2012), thereby enabling detection of either enhanced or attenuated temperature and locomotor
effects following repeated injection (Green et al., 2014). In the current study, all experiments
were performed at ambient temperature as Wright et al, (2012) observed that mephedrone
produced a comparable hypothermia and increase in locomotor activity when recorded at
normal (23
o
C) and elevated (27
o
C) ambient room temperature in Wistar rats.
The current repeat dosing studies used continuous radiotelemetry to accurately and
repeatedly record locomotor activity and core body temperature over a prolonged period in
the same animal, without repeated insertion of a rectal probe, which would confound
assessment of activity, at a consistent dose interval to previous preclinical studies using
MDMA or mephedrone (Baumann et al., 2012; Baumann et al., 2008; Rodsiri et al., 2011).
Because mephedrone causes hyperlocomotion (Shortall et al., 2013b) and the striatum plays a
role in motor activity (Schultz, 2000), extracellular dopamine and 5-HT efflux from this
6region were measured by in vivo microdialysis to examine whether neurotransmitter release
correlated with the behavioral effects.
Previous pharmacological studies suggest the involvement of dopamine in
mephedrone-induced hypothermia (Shortall et al., 2013a), so we further examined the
contribution of serotonergic and dopaminergic neurons to the behavioral effects of
mephedrone. Intracerebroventricular (i.c.v.) pre-treatment with selective neurotoxins (5,7-
dihydroxytryptamine (5,7-DHT) and 6-hydroxytryamine, 6-OHDA, respectively) was used to
determine the impact of 5-HT or dopamine depletion on the thermoregulatory and locomotor
stimulant effects of repeated mephedrone measured using radiotelemetry. After identifying a
role of 5-HT in mephedrone-induced hyperactivity and hypothermia, a final acute study
investigated the involvement of specific 5-HT receptors by assessing the impact of selective
5-HT1A, 5-HT1B or 5-HT7 receptor antagonists on acute mephedrone-induced
hyperlocomotion or hypothermia. These receptors were chosen because of their known role
in locomotion and/or thermoregulation in the rat and to permit comparisons with the
published effects of MDMA. Radiotelemetry was not used in these studies in accordance with
the three Rs principle that invasive surgical implantation was unnecessary for acute
measurement. This is the first study to concomitantly examine the effects of repeated
mephedrone on hyperactivity, hypothermia and striatal dopamine efflux in short time periods
(to provide a good temporal resolution) and establish the differential role of dopamine and 5-
HT in mephedrone-induced hyperactivity and hyperthermia for comparison with the
established effects of repeated MDMA injection.
Materials and Methods
Animals
7Experimentally naïve young adult male Lister hooded rats (190-300g; Charles River UK)
were used in all experiments. Rats were housed in groups of four prior to surgery and in
individual cages post-surgery, under constant housing conditions (12 hours light:dark cycle
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Food and water were freely available, and wet mash was provided for five days post-surgery.
The drug doses and behavioral schedule used were chosen to comply with the three
Rs of humane animal testing. All experiments were conducted in accordance with the
Animals (Scientific Procedures) Act, 1986 and Animal Research: Reporting of In Vivo
Experiments guidelines with approval of University of Nottingham Local Ethical Committee.
Compounds
(±)-Mephedrone-HCl was purchased from Ascent Scientific, Cambridge, UK. Desipramine
hydrochloride, ascorbic acid, 6-hydroxydopamine (6-OHDA) hydrobromide, N-[2-[4-(2-
methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridyl)cyclohexanecarboxamide maleate (WAY-
100635), N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-2'-methyl-4'-(5-methyl-1,2,4-
oxadiazol-3-yl)-1,1'-biphenyl-4-carboxamide hydrochloride (GR 127935) and (1R)-3,N-
dimethyl-N-[1-methyl-3-(4-methylpiperidin-1-yl)propyl]benzenesulfonamide hydrochloride
(SB-258719) were purchased from Tocris Bioscience, Bristol, UK. 5-7-dihydroxytryptamine
(5,7-DHT) creatine sulphate was purchased from Sigma Aldrich, Dorset, UK. Mephedrone,
desipramine, WAY-100635, GR 127935 and SB-258719 were dissolved in 0.154M saline,
and 6-OHDA and 5,7-DHT were dissolved in 0.2% w/v ascorbic acid. All doses are quoted as
the salt.
Radiotelemetry
8Radiotelemetry was conducted as previously described (Rodsiri et al., 2011). Sterile radio-
transmitters (Model TA 10TA-F20, DataScience International St Paul, MN, USA) were
surgically implanted into the peritoneal cavity under isoflurane anesthesia. Post-operative
analgesia was administered for 3 days (Rimadyl (carprofen), Pfizer; 4mg/kg, subcutaneous)
and rats were allowed to recover for 9 days, then transferred to the procedure room 24 hours
prior to testing to habituate. During testing, core body temperature and activity were
continuously monitored in the home cage at ambient room temperature (19.9-20.9°C), using
receivers (RPC-1) and A.R.T. v4 acquisition software (DataScience International, St Paul,
MN, USA). Rats (n=5 per treatment group) received three i.p. injections of either saline
vehicle (1ml/kg) or mephedrone (10mg/kg) at 2 hour intervals. Data were collected for 10
seconds every 2 minutes starting 60 minutes prior to the first injection, grouped into 20
minute epochs and expressed as mean ± standard error of the mean (SEM) activity counts.
The change in body temperature (°C) from the baseline reading at 0 minute immediately prior
to drug injection and the total cumulative activity counts in the 120 minutes following each
injection were calculated and presented as mean ± SEM.
Microdialysis
As our Animals (Scientific Procedures) Act, 1986 project licence did not permit
radiotelemetry and microdialysis to be performed in the same animal, microdialysis was
measured in a separate cohort of rats using an identical protocol as previously described
(Rodsiri et al., 2011). A CMA 12 polyurethane guide cannula (CMA Microdialysis AB,
Kista, Sweden) was implanted above the striatum using stereotaxic coordinates anterior-
posterior +0.48, medial-lateral ±3.0, dorsal-ventral -3.6 from Bregma (Paxinos and Watson,
1997) under isoflurane anesthesia. Seven days post-surgery, rats were briefly anaesthetized
(isoflurane/O2/N2O) to insert a microdialysis probe (CMA12, 4mm polyarylethersulpone
9membrane, 500µm outer diameter, 3µl internal volume with a 20kDa molecular cut-off;
CMA Microdialysis AB) and each rat then placed in a circular arena (50cm diameter, 45cm
height) with sawdust bedding, and food and water freely available. The probe was connected
to a microinfusion pump (Harvard Apparatus, Holliston, MA, USA) using FEP tubing
(Instech Laboratories Inc, Plymouth Meeting, PA, USA) via a liquid swivel (Instech 375/22,
Instech Laboratories Inc, USA) to allow unrestricted movement and perfusion with artificial
cerebrospinal fluid (125mM NaCl, 13.5mM NaHCO3, 1.25mM KCl, 0.22mM NaH2PO4,
0.9mM Na2HPO4, 0.3mM Na2SO4, 0.5mM MgCl2, 0.5mM CaCl22H2O, pH 7.4) at 1µl/min.
The following day, rats (n=10 per treatment group) received three injections at 2 hour
intervals of saline vehicle (1ml/kg) or mephedrone (10mg/kg i.p.), and samples were
collected every 20 minutes into microtubes containing 5µl of 0.1M perchloric acid with
0.03% sodium metabisulfite. Samples were immediately stored on dry ice and then at -80°C
until analysis by high performance liquid chromatography-electrical detection. After a
collection of the final microdialysis sample, rats were euthanized with pentobarbital. Brains
were rapidly removed and stored in 4% paraformaldehyde until sectioned (150µm coronal
slices) using a vibrotome (Campden Instruments Ltd, Loughborough, UK). Location of the
probe in the striatum was confirmed under a light microscope using Paxinos and Watson Rat
Brain Atlas (1997).
Dopamine and 5-hydroxytrptamine depletion
In a third group of rats, bilateral i.c.v. injection of a monoamine neurotoxin (5,7-DHT or 6-
OHDA) was performed under isoflurane anesthesia as previously described (King et al.,
2009). All rats received desipramine (15mg/kg, i.p., 30 minute pre-treatment) to protect
noradrenergic neurons prior to 5µl of 0.2% w/v ascorbic acid vehicle, 75µg/5µl of 5,7-DHT
or 150µg/5µl of 6-OHDA into each lateral ventricle anterior-posterior -0.8, medial-lateral
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±1.5, dorsal-ventral -3.8 from Bregma (Paxinos and Watson, 1997) at a rate of 5µl/minute.
These doses were chosen as they reportedly produce a similar degree of depletion (70-75%
below control value; King et al, 2009; Nowak et al, 2009). Twenty-one days post-surgery,
each rat (n=8 per treatment group) received three injections of saline vehicle (1ml/kg) or
mephedrone (10mg/kg i.p.) at 2 hour intervals, with radiotelemetry measurements as
described previously. Using a cross-over design, rats received the opposite treatment during
repeat monitoring 28 days post-surgery to minimize inter-individual responses to drug
treatment or the lesion.
Neurochemical detection by high performance liquid chromatography-electrical
detection
Seven days after radiotelemetry recording (35 days after i.c.v. injection), rats were killed by
concussion followed by immediate decapitation, and the hypothalamus, right striatum, frontal
cortex and hippocampus were collected on a refrigerated table (4°C), flash frozen in liquid
nitrogen and stored at -80°C until analysis of dopamine, 5-HT and their major metabolites by
high performance liquid chromatography-electrical detection, as previously described
(Shortall et al., 2013b). Samples were thawed, weighed and sonicated for 30s in 800µl 0.05M
perchloric acid containing 1µM sodium metabisulphite, centrifuged (17400xg, 4°C for
20min; Harrier 18/80: MSE Scientific Instruments, London, UK) and the supernatant filtered
(0.45µM syringe tip filter, Kinesis Ltd, Saint Neots, UK). Monoamines were separated using
a Targa C18 3µMVcolumn (100mm x 2.1mm; Phenomenex, Cheshire, UK) and detected
using an Antec VT-03 cell with a glassy carbon 2mm working electrode set to +0.59V with
an in situ Ag/AgCl ISAAC reference electrode. This system was also used to quantify
extracellular dopamine and 5-HT in microdialysis samples. In addition, noradrenaline levels
were measured in the same regions in 5,7-DHT and 6-OHDA pre-treated rats using a
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modified HPLC protocol (a mobile phase of 20mM KH2PO4/Na acetate, 8mM KCl, 0.1mM
EDTA, 1mM OSA, containing 10% methanol, pH 4.07).
Effect of 5-HT1A, 5-HT1B and 5-HT7 receptor antagonists on mephedrone-induced
hyperactivity and hypothermia following a single injection
Locomotor activity (LMA) and rectal temperature were recorded from separate groups to
establish the role of specific 5-HT receptors in acute mephedrone-induced hyperactivity and
hypothermia, using previously described methods (Shortall et al., 2013a; Shortall et al.,
2013b). Rats (n=8 per treatment group) received saline vehicle (1ml/kg, i.p.), the 5-HT1A
receptor antagonist WAY-100635 (0.5mg/kg), the 5-HT1B receptor antagonist GR 127935
(3mg/kg) or the 5-HT7 receptor antagonist SB-258719 (10mg/kg), followed 30 minutes later
by vehicle (1ml/kg, i.p.) or mephedrone (10mg/kg). Doses of 5-HT receptor antagonists were
selected from previous studies (Fletcher et al., 2002; Graf et al., 2004; Guscott et al., 2003;
Rusyniak et al., 2007).
Locomotor activity
Rats were placed in individual Perspex arenas and allowed to habituate for 60 minutes prior
to the first injection. LMA was continuously recorded (in 5 minute time bins) for 30 minutes
after the first and 60 minutes after the second injection using a Photobeam Activity System
(San Diego Instruments, CA, USA) to record ambulation and rears.
Rectal temperature
In acute drug studies, rats were placed in individual Perspex arenas and basal temperature
measured 40 minutes prior to the first injection to allow habituation to the recording
procedure, which involved insertion of a rectal probe (Portec Instrumentation, Bedfordshire,
12
UK) to a depth of 6.5cm for approximately 20 seconds. Rectal temperature was measured
immediately prior to each injection and then at 20 minute intervals for the next 2 hours.
Statistical Analysis
Analyses were performed using GraphPad Prism v6.02 or SPSS v21 software.
Radiotelemetry data were analyzed by two-way repeated measures analysis of variance
(ANOVA, with drug treatment and time as between and within factors, respectively) where
rats received vehicle or mephedrone alone, or four-way repeated measures ANOVA (applied
separately to 5,7-DHT and 6-OHDA groups, with i.c.v. injection and drug as between factors
and time and week as within factors) where they also received i.c.v. injections. Dopamine
microdialysis data were analyzed by two-way repeated measures ANOVA (with drug
treatment and time as between and within factors, respectively). 5-HT microdialysis data
were analyzed by one sample t-test against the pre-injection basal value as vehicle values fell
below the limit of detection after 40 minutes. HPLC data were analyzed by one-way
ANOVA where rats received vehicle or mephedrone alone, or two-way ANOVA where they
also received i.c.v. injections. Acute LMA and rectal temperature data were analyzed by
three-way repeated measures ANOVA (with 5-HT receptor antagonist pre-treatment and
mephedrone treatment as between factors and time as the within factor). Total cumulative
activity counts were analyzed by two-way ANOVA (with pre-treatment and treatment as
between factors). Bonferroni multiple comparisons post-hoc test was used where appropriate
and P<0.05 was considered statistically significant. All data are presented as mean ± SEM.
Results
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Effects of repeated mephedrone on locomotor activity, body temperature and in vivo
striatal dopamine release
Locomotor activity
Mephedrone increased activity above vehicle control levels for 40 minutes after the first
injection and 80 minutes after the second and third injections, such that there was a drug x
time interaction (F(18,144)=3.43, P<0.001, Fig. 1a). The response to vehicle appeared to
diminish with each consecutive administration, whereas the magnitude of the mephedrone-
induced increase was similar after each injection.
Analysis of total cumulative activity in the 2 hours following each injection confirmed
that mephedrone caused a reproducible hyperactivity on each occasion, with no significant
difference between injections (First: 580±56; Second: 567±98; Third: 416±115 counts/2
hours). The peak response (increase compared with each pre-injection value) was also similar
(7.2 ± 2.2; 8.2 ± 3.3; 7.9 ± 2.7). However, in vehicle-treated rats, the total decreased from
197±105 following the first to 61±15 after the third administration (P<0.05), suggesting some
habituation to injection, which was not observed following mephedrone. This was reflected
by a drug x injection number interaction (F(2,16)=3.87, P<0.05), which was attributed to the
change in the vehicle rather than mephedrone response.
Core body temperature
There were no between-group differences in temperature (recorded simultaneously with
locomotor activity) in the 60 minutes prior to injection (data not shown), with baseline values
(at the time of the first injection) being 37.8 ± 0.2°C in rats due to receive vehicle and 37.9 ±
0.1°C in those due to receive mephedrone. Following injection there was a drug x time
interaction: (F(18,144)=4.26, P<0.001, Fig. 1b), and although mephedrone decreased body
14
temperature to a greater extent than vehicle from 40-60 minutes after the first injection only,
the maximum temperature change from baseline following each consecutive mephedrone
injection was similar, being -1.3, -1.4 and -1.2°C following the first, second and third
injections respectively. However, temperature did not return to baseline between injections,
and the magnitude of each further decrease (compared with immediate pre-injection values;
at T0, T120, T240) was attenuated (First: -1.3 ± 0.3°C; Seconds: -0.6 ± 0.3°C; Third: -0.2 ±
0.2°C reaching significance for the last injection; P<0.05 from the first response) suggesting
tolerance occurred.
In vivo striatal dopamine and 5-hydroxydopamine efflux
In a separate group of rats to those used for radiotelemetry, there were no between-group
differences in basal extracellular dopamine levels in the 60 minutes prior to the first injection
(7.32 ± 1.65pmol/ml in rats due to receive vehicle and 5.08 ± 0.85pmol/ml in those due to
receive mephedrone). Following injection, there was a drug x time interaction (F(18,319)=3.55,
P<0.001, Fig. 1c). Mephedrone rapidly increased extracellular dopamine levels above vehicle
control for 40 minutes after the first and third injections and 60 minutes after the second, but
dopamine levels returned to near basal between injections. Thus, each injection produced a
similar magnitude (First: 298%; Second: 520%; Third: 435% peak change from baseline) and
time course of elevation in extracellular striatal dopamine.
Basal extracellular levels of 5-HT were close to the detection limit but equivalent in
both groups when measured immediately prior to the first injection (0.295 ± 0.12 and 0.323 ±
0.07pmol/ml in control and mephedrone groups, respectively). In vehicle-treated rats, post-
injection 5-HT levels remained either close to or below the detection limit, and the pre-
injection value has been used to calculate the percentage increase (Fig. 1d). The first
mephedrone injection failed to elevate extracellular 5-HT, but the two subsequent injections
15
produced statistically significant increases (P<0.05 to P<0.01, versus mean baseline 60
minutes after the second [458% peak change from baseline] and 40 minutes after the third
injection [351% peak change from baseline]).
Ex vivo monoamine content
There was no significant effect of repeated mephedrone administration on tissue levels of
dopamine, 5-HT or their major metabolites in the hypothalamus, striatum, hippocampus or
frontal cortex measured 7 days after radiotelemetry recording (data not shown).
Effects of 5-HT or dopamine depletion on repeated mephedrone-induced changes in
locomotor activity and core body temperature
Locomotor activity
The third experiment again found that mephedrone caused a rapid increase in locomotor
activity, which returned to basal levels between injections, whereas vehicle produced only a
very small transient response in the same rats. Four-way repeated measures ANOVA
confirmed a drug x 5,7-DHT (F(1,28)=4.92, P<0.001) and drug x time interactions
(F(18,504)=9.32, P<0.001), but no drug x 5,7-DHT x time interaction (F(18,504)=1.24, P>0.05,
Fig. 2a). Of note, 5,7-DHT pre-treatment attenuated the mephedrone-induced hyperactivity,
such that there was no significant response of 5,7-DHT-treated rats to the first mephedrone
injection and responses to the second and third mephedrone injections were significantly
lower in 5,7-DHT-treated rats than sham controls (while the response to vehicle was
unaffected). In contrast, 6-OHDA lesion did not alter mephedrone-induced hyperactivity
(drug x 6-OHDA x time: F(1,28)=1.66, P>0.05, Fig. 2b).
Consistent with the previous experiment, total cumulative activity in the 2 hours
following each injection confirmed mephedrone-induced hyperactivity, with a drug x
16
injection number interaction (F(2,36)=5.31, P<0.01, Table 1). 5,7-DHT completely prevented
the response to the first mephedrone injection and attenuated that to the third (P<0.01versus
sham control mephedrone response). In contrast, 6-OHDA-treated rats continued to exhibit
an increase in cumulative activity following each mephedrone injection which did not differ
from the response in mephedrone-treated sham controls.
Core body temperature
Basal core body temperatures prior to the first injection on each test day (recorded
simultaneously with locomotor activity in the same sham and lesioned rats) were equivalent,
being 37.2 ± 0.2 and 37.5 ± 0.2°C in sham controls, 36.9 ± 0.2 and 37.2 ± 0.2°C in 5,7-DHT
and, 37.5 ± 0.2 and 37.4 ± 0.2°C in 6-OHDA rats prior to injection of vehicle or mephedrone,
respectively. The maximum temperature change from baseline following each mephedrone
injection in sham controls (-1.2, -1.2 and -1.0°C following the first, second and third
injections, respectively) was equivalent, but in agreement with the first study, the maximum
temperature decrease (compared with pre-injection value) was attenuated following both the
second and third (P<0.05) compared with the first injection (First: -1.2 ± 0.2°C; Second: -0.3
± 0.1°C; Third: -0.1 ± 0.2°C).
There was a main drug x 5,7-DHT x time interaction (F(18,504)=1.72, P<0.05; Fig.
2c,d) such that mephedrone significantly reduced core body temperature in sham controls 20-
80 minutes after the first, 20-60 minutes after the second and at 40 and 80 minutes after the
third injection. 5,7-DHT pre-treatment completely abolished mephedrone-induced
hypothermia, and there was no difference between vehicle and mephedrone-treated 5,7-DHT
rats at any time point, and the temperature change in 5,7-DHT mephedrone-treated rats was
significantly attenuated compared to mephedrone-treated sham controls. There was also a
main drug x 6-OHDA x time interaction (F(18,504)=1.76, P<0.05), such that mephedrone-
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induced hypothermia was reduced in 6-OHDA pre-treated rats where the decrease in
temperature was only significant from sham controls at 40-80 minutes and at 40 minutes
following the first and second injections, respectively.
Ex vivo neurochemistry
Dopamine, 5-HT and noradrenaline levels in the hypothalamus, right frontal cortex,
hippocampus and striatum were measured 35 days after neurotoxin administration to confirm
selective monoamine depletion. As expected the serotonergic neurotoxin, 5,7-DHT,
significantly reduced 5-HT to 46% of control in the frontal cortex (P<0.001), 13% in the
hippocampus (P<0.01), 42% in the hypothalamus (P<0.001) and 66% in the striatum
although the latter did not reach significance due to high individual variation (Table 2). In
contrast, 6-OHDA reduced dopamine to 52% of control in the striatum (P<0.001) and 56%,
80% and 86% of control in the frontal cortex, hippocampus and hypothalamus, respectively,
although the depletion in these areas was not statistically significant (Table 2). However, the
6-OHDA-induced decrease in striatal dopamine was accompanied by a significant reduction
in hippocampal 5-HT (F(2,20)=7.19, P<0.01) as well as decreased noradrenaline levels in the
hypothalamus and hippocampus (F(2,21)=9.53, P<0.001), but noradrenaline levels were
unchanged in the other regions examined.
Effect of 5-HT1A, 5-HT1B and 5-HT7 receptor antagonists on acute mephedrone-induced
hyperactivity and decreases in rectal temperature
In a final study, separate groups of rats were pre-treated i.p. with the 5-HT1A receptor
antagonist, WAY-100635, the 5-HT1B receptor antagonist, GR 127935, or the 5-HT7 receptor
antagonist, SB-258719 to investigate the role of specific 5-HT receptors in mephedrone-
induced hyperactivity and hypothermia.
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Locomotor activity
None of the three 5-HT receptor antagonists had any effect on activity counts following their
injection (data not shown). The predominant locomotor stimulant effect of mephedrone in
vehicle pre-treated rats was a prolonged increase in ambulatory activity (p<0.05-0.001,
accompanied by a smaller increase in fine movement without increased rearing consistent
with previous studies by our group (Shortall et al., 2013b) and the current telemetry data. It
was briefly attenuated WAY-100653 (Fig. 3a) at 15 minutes post-injection and more
substantially attenuated by GR 127935 (Fig. 3b) from 15-35 minutes post-injection, but
completely unaffected by SB-258719 (Fig. 3c). Consistent with the time-course data, total
cumulative ambulation in the 60 minutes post-mephedrone period was reduced from
1244±199.1 in vehicle pre-treated rats to 706.8±78.4 by GR 127935 pre-treatment (pre-
treatment x mephedrone interaction: F(1,28)=5.39, p<0.05), but unaffected by WAY-100653
(1007±129.6) or SB-258719 (1557±176.7).
Rectal temperature
Injection of vehicle had no effect on rectal temperature irrespective of whether rats were pre-
treated with WAY-100635 (Fig. 4a), GR 127935 (Fig. 4b) or SB-258719 (Fig. 4c).
Mephedrone caused a transient but significant decrease in rectal temperature at 20 minutes
(P<0.001) and 40 minutes (P<0.05) post-injection compared with vehicle, which was
consistent with the duration and magnitude observed in a previous study by our group
(Shortall et al., 2013a). There was a WAY-100635 x mephedrone x time interaction
(F(7,196)=2.84, P<0.01, Fig. 4a), such that the mephedrone-induced hypothermia was partially
blocked by WAY-100635 from 20-40 minutes post-mephedrone. However, there was no
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significant GR 127935 x mephedrone x time interaction (F(7,196)=1.16, P>0.05, Fig. 4b) nor a
SB-258719 x mephedrone x time interaction (F(7,196)=1.35, P>0.05, Fig. 4c).
Discussion
This study investigated the effects of repeated mephedrone injection on core body
temperature, locomotor activity and striatal dopamine and 5-HT release in the rat, and
examined the role of dopamine and 5-HT containing neurons on mephedrone-induced
changes in body temperature and activity. This is one of only a few studies to use
radiotelemetry to obtain a high temporal resolution of changes appropriate for the short-
duration responses (Aarde et al., 2013; Miller et al., 2012; Wright et al., 2012). The main
findings were as follows; (1) while hyperactivity and increase in extracellular striatal
dopamine seen after the first mephedrone injection were similar in magnitude and time
course to those seen following the second and third injections, the hypothermia was
attenuated with repeated dosing; (2) extracellular striatal 5-HT overflow was more variable
but was enhanced when second and third injections were given when compared with the first
response; (3) 6-OHDA did not affect hyperactivity but reduced the duration of the
hypothermic response; (4) 5,7-DHT administration and 5-HT1B receptor antagonism
attenuated mephedrone-induced hyperactivity; (5) 5,7-DHT administration completely
abolished, and 5-HT1A receptor antagonism attenuated mephedrone-induced hypothermia.
Importantly, some of these observed effects contrast with those reported with MDMA,
suggesting differing possible adverse effects following recreational use.
Mephedrone has a high affinity for rat dopamine and 5-HT transporters as well as the
5-HT2A and 5-HT2C UHFHSWRUV DQG Į1A DQG Į2A-adrenoceptors (Eshleman et al., 2013;
Martinez-Clemente et al., 2012; Simmler et al., 2013). It increases extracellular dopamine
and to an even greater extent 5-HT in the nucleus accumbens (Baumann et al., 2012;
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Eshleman et al., 2013; Kehr et al., 2011; Wright et al., 2012). The current study, in contrast,
suggests that in the striatum, the percentage increase in 5-HT and dopamine is rather similar,
at least after the second and third injections.
The repeated dose given in the current study (10mg/kg) did not produce any
neurotoxic loss of brain regional dopamine or 5-HT measured 7 days post-injection. This is in
marked contrast to MDMA, where a repeated dose schedule that releases striatal dopamine
also produces significant long-term neurotoxic 5-HT depletion in the rodent (Green et al.,
2003), but similar to methcathinone where a much larger dose than that needed to elicit
behavioral changes is required to obtain neurotoxicity (Sparago et al., 1996). Although
hypothermia protects against MDMA neurotoxicity (Malberg and Seiden, 1998), a previous
study in which mephedrone produced hyperthermia in the rat also failed to detect any
neurotoxic loss of post-mortem brain monoamines two weeks after a repeated dosing
schedule similar to that used in the current study (Baumann et al., 2012). These data therefore
suggest that rapid repeated mephedrone administration is less likely to produce monoamine
neurotoxicity than MDMA.
Mephedrone induces hyperactivity in rodents following both acute and intermittent
administration (Angoa-Perez et al., 2012; Baumann et al., 2012; Kehr et al., 2011; Marusich
et al., 2012; Shortall et al., 2013b; Wright et al., 2012). Mephedrone (0.5 to 30 mg/kg i.p. or
subcutaneous) has consistently been shown to elicit hyperactivity in a variety of rat strains,
when given during both the light (Gregg et al., 2013; Lisek et al., 2012; Shortall et al., 2013b)
or dark (Miller et al., 2013; Motbey et al., 2012) phase of the circadian cycle. Because
significant hyperactivity was found irrespective of circadian phase, the current study was
conducted in the light phase to enable comparison with the many studies on MDMA,
including our own, which use this protocol. In the current study, repeated ‘binge-style’
mephedrone administration caused reproducible hyperactivity after each injection, the onset
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of which occurred within minutes of injection but returned to baseline levels within 1 hour.
The time courses for both the striatal dopamine release and the hypothermia are consistent
with a previous study using a single systemic injection (Shortall et al., 2013b). It is
noteworthy that the peak plasma level of mephedrone in the rat follows a similar temporal
pattern following subcutaneous injection (Miller et al., 2013). Importantly, the total
ambulatory activity counts following the second and third injections of mephedrone were
comparable to those following the first injection. This response therefore differs markedly
from MDMA where progressively increasing hyperactivity was observed following a similar
repeated dosing schedule (Rodsiri et al., 2011).
In the current study, central 5-7-DHT administration markedly attenuated the
hyperactivity observed following mephedrone injection 21 or 28 days later, while i.c.v.
injection of 6-OHDA had no effect on mephedrone-induced hyperactivity. This observation is
consistent with the ability of pCPA-induced 5-HT depletion to reduce mephedrone-induced
hyperactivity in mice (Lopez-Arnau et al., 2012) and supports a key role for 5-HT in
mephedrone-induced hyperactivity. In the current study blockade of 5-HT1B, and to a lesser
extent 5-HT1A (but not 5-HT7), receptors also reduced mephedrone-induced hyperactivity,
and this is consistent with similar observations on MDMA-induced hyperactivity (Fletcher et
al., 2002; McCreary et al., 1999). The affinity of mephedrone for the 5-HT1B receptor has not
yet been investigated and so it is difficult to ascertain whether this effect on mephedrone-
induced hyperactivity is due to a direct effect on this receptor.
Although hyperthermia has not been recorded in mephedrone users, there is evidence
that it alters peripheral thermoregulation because reported adverse effects include cold/blue
fingers, hot flushes and sweating (Winstock et al., 2011; Wood and Dargan, 2012) which may
occur from peripheral changes in blood flow. Earlier studies have generally failed to observe
hyperthermia in rodents given an acute injection of mephedrone, even when the animals are
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group-housed or kept in raised ambient temperature (Shortall et al., 2013a; Wright et al.,
2012). However, hyperthermia was observed in two studies investigating the effects of
repeated mephedrone injection (Baumann et al., 2012; Hadlock et al., 2011). Of note, both of
these studies used Sprague Dawley rats and subcutaneous injections so there could be strain
and/or pharmacokinetic differences (Wright et al., 2012). These repeated injection studies
also used a rectal probe to measure the response at 1 hour intervals so the observed
hyperthermia may have resulted from an additive effect of repeated mephedrone injection
combined with stress-induced hyperthermia associated with rectal measurement as evident in
vehicle control animals (Baumann et al., 2012; Hadlock et al., 2011). The current study
therefore used radiotelemetry to measure the temperature response following repeated
mephedrone injection and showed it produced hypothermia as reported following a single
injection (Aarde et al., 2013; Miller et al., 2012). In the current study, 5,7-DHT
administration abolished the hypothermic response to mephedrone. Furthermore,
administration of the 5-HT1A receptor antagonist, WAY-100635, attenuated mephedrone-
induced hypothermia while antagonism of the 5-HT1B or 5-HT7 receptors had no effect.
Although 5-HT1A receptors are implicated in the hypothermic response, their involvement is
almost certainly a consequence of 5-HT release and/or inhibition of reuptake, because the low
affinity of mephedrone for the 5-HT1AUHFHSWRU.L!ȝ06LPPOHUHWDOPDNHVDQ\
direct effect unlikely. Interestingly, pre-treatment with WAY-100635 at the same dose as
used herein also prevents the hypothermic response to MDMA (Rusyniak et al., 2007) but the
involvement of 5-HT1B and 5-HT7 receptors in the thermoregulatory effect of MDMA has not
been documented. In contrast, mephedrone injection to 6-OHDA-treated rats produced a
hypothermic response which was shorter in duration than that seen in sham controls. At first,
this appears paradoxical because we have shown that administration of the dopamine D1
receptor antagonist, SCH 23390, prolonged mephedrone-induced hypothermia (Shortall et al.,
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2013a). However, the limited depletion of dopamine in the hypothalamus makes it difficult to
come to any firm conclusion about the role of dopamine in mephedrone-induced
hypothermia.
Tolerance to the hypothermic effect of mephedrone is intriguing and is unlikely to be
due to a pharmacokinetic effect as locomotor and dopamine responses were unaffected.
Considerable evidence shows that 5-HT plays a major role in thermoregulation, particularly
when body temperature is perturbed by amphetamine-like drugs (Docherty and Green, 2010).
However, it is unclear whether increased 5-HT release with repeated dosing, observed herein,
is associated with tolerance to the hypothermic effect of mephedrone. Although the limited
depletion of hypothalamic dopamine makes it impossible to completely exclude a role of this
monoamine in mephedrone-induced hypothermia the fact that this response is unaffected by
dopamine D2 receptor blockade and prolonged by D1 receptor antagonism (Shortall et al.,
2013a) suggests that mephedrone-induced increases in dopamine efflux are unlikely to
contribute to the drug-induced hypothermia. In contrast, modulation of central serotonergic
neurotransmission plays a key role in mediating both the hyperlocomotor and hypothermic
effects of mephedrone.
Although caution is required in attempting to translate the relevance of these findings
in the rat to those in man, they demonstrate the need to evaluate the pharmacology and
psychoactive effects of any new amphetamine analogues and not rely on prediction from
structural analogy.
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Table 1 Total activity counts following repeated mephedrone administration to 5-HT or
dopamine depleted rats
Lesion Type Treatment Injection 1 Injection 2 Injection 3
Sham V 285 ± 63 149 ± 25 139 ± 23

Meph 579 ± 77** 619 ± 70*** 572 ± 73***
5,7-DHT V 226 ± 40 123 ± 23 134 ± 26
Meph 382 ± 44 444 ± 43**

313 ± 50

6-OHDA V 298 ± 50 132 ± 20
 182 ± 57
Meph 743 ± 63***

766 ± 72***

667 ± 39***

ANOVA = analysis of variance; SEM = standard error of the mean; 5-HT = 5-
hydroxytrptamine; 5,7-DHT = 5,7-dihydroxytrptamine; 6-OHDA = 6-hydroxydopamine.
Horizontal ambulatory counts (mean ± SEM) were measured following each of three i.p.
injections of saline vehicle (V, 1ml/kg) or mephedrone (Meph, 10mg/kg) at 2 hour intervals,
21 or 28 days after bilateral i.c.v. injection under isoflurane anesthesia of either 0.2%
DVFRUELFDFLGYHKLFOHȝO'+7ȝJȝOSHUVLGHRU2+'$ȝJȝOSHUVLGHWR
individually housed adult male Lister hooded rats (n = 8 per treatment group). ***P<0.001,
**P<0.01 sham + mephedrone compared to sham + vehicle; ***P< 0.001, **P< 0.01 lesion
+ mephedrone compared to sham + vehicle, P<0.001, P<0.05 lesion + mephedrone
compared to lesion + vehicle, P<0.01 lesion + mephedrone compared to sham +
mephedrone, P<0.05 compared to the first injection of the same treatment group,
Bonferroni multiple comparisons post hoc following three-way repeated measures ANOVA.
Of note, 5,7-DHT reduced the hyperactivity produced by mephedrone (it was no longer
greater than the effect of vehicle) while 6-OHDA did not attenuate the activity response to
mephedrone.
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Table 2 Effect of i.c.v. administration of 6-OHDA or 5,7-DHT on brain tissue dopamine, 5-
HT and noradrenaline levels 5 weeks post-surgery
Tissue levels (pmol/mg)
Lesion Type Frontal cortex Hippocampus Hypothalamus Striatum
Dopamine
Sham 0.72 ± 0.2 0.4 ± 0.03 3.0 ± 0.2 55.6 ± 4.5
5,7-DHT 0.46 ± 0.02 0.4 ± 0.02 3.4 ± 0.2 60.4 ± 2.2
6-OHDA 0.40 ± 0.02 0.3 ± 0.01 2.5 ± 0.2 28.6 ± 5.5***
5-HT
Sham 3.5 ± 0.3 3.8 ± 0.4 7.2 ± 0.5 4.4 ± 0.3
5,7-DHT 1.6 ± 0.3*** 0.5 ± 0.1*** 3.0 ± 0.4*** 2.9 ± 0.5
6-OHDA 4.0 ± 0.2 1.9 ± 0.6* 5.4 ± 0.6 5.5 ± 0.5
Noradrenaline
Sham 1.8 ± 0.1 2.8 ± 0.3 16.8 ± 1.5 0.9 ± 0.1
5,7-DHT 1.9 ± 0.1 2.2 ± 0.5 15.9 ± 1.5 1.1 ± 0.2
6-OHDA 1.7 ± 0.1 0.9 ± 0.2** 8.5 ± 1.4** 1.0 ± 0.3
ANOVA = analysis of variance; SEM = standard error of the mean; 5-HT = 5-
hydroxytrptamine; 5,7-DHT = 5,7-dihydroxytrptamine; 6-OHDA = 6-hydroxydopamine.
Dopamine, 5-HT and noradrenaline levels (mean ± SEM, pmol/mg wet weight) were
PHDVXUHGGD\VDIWHUELODWHUDOLFYLQMHFWLRQRIHLWKHUDVFRUELFDFLGYHKLFOHȝOSHU
VLGH'+7ȝJȝOSHUVLGHRU2+'$ȝJȝOSHUVLGHWRLQGLYLGXDOO\KRXVHG
male Lister hooded rats (n=8 per treatment group). ***P<0.001, **P<0.01, *P<0.05
compared to sham controls, Bonferroni post hoc following one-way ANOVA. Note that 5,7-
DHT selectively reduced 5-HT in the frontal cortex, hippocampus and hypothalamus while 6-
OHDA depleted dopamine in the striatum without affecting noradrenaline and 5-HT in this
region.
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Fig. 1. Comparison of the effect of repeated injection of saline vehicle (V, 1ml/kg i.p., n=5)
or mephedrone (Meph, 10mg/kg, n=5) on (a) locomotor activity, (b) core body temperature
and in vivo extracellular striatal (c) dopamine and (d) 5-HT levels (n=10 per treatment group)
in individually housed adult male Lister hooded rats. Vehicle or mephedrone were injected
once every 2 hours at 0, 120 and 240 minutes (as indicated by the arrows). Temperature data
are represented as change from baseline (t = 0 min, °C). All data are presented as mean ±
SEM and (a-c) *P<0.05, **P<0.01, ***P<0.001 compared to vehicle, Bonferroni multiple
comparisons post-hoc following two-way repeated measures ANOVA. (d) 5-HT levels fell
below the detection limit in most rats at more than 40 minutes after starting microdialysis
collection preventing data for subsequent time points to be displayed so the change in 5-HT
in the mephedrone group was analyzed against the pre-injection basal value (0.350 +
0.091pmol/ml) using one sample t test, **P<0.01. For clarity of presentation, microdialysis
data (c,d) are displayed as percentage change from baseline, but statistical analysis was
performed on the raw data.
)LJ(IIHFWVRIELODWHUDO LFY LQMHFWLRQ ȝOSHU VLGHRIDVFRUELFDFLGYHKLFOH
'+7 JȝO SHU VLGH RU 2+'$ JȝO SHU VLGH E G SUHWUHDWPHQW RQ VDOLQH
vehicle (1ml/kg) or mephedrone (10mg/kg) induced change in (a, b) ambulatory activity
counts and (c,d) core body temperature change from baseline (at t = 0 min, °C) in adult male
Lister hooded rats (n=8 per treatment group). Using a cross over design, each rat received
vehicle or mephedrone on day 21, and the opposite treatment 28 days post-surgery. Vehicle
and mephedrone were injected once every two hours at 0, 120 and 240min (as indicated by
the arrows). All data are presented as mean ± SEM. For clarity 5,7-DHT and 6-OHDA have
been presented as separate Fig.s versus the sham controls but ANOVA has been performed
on all groups. *P<0.05, **P<0.01, ***P<0.001 sham mephedrone compared to sham +
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vehicle ; ***P< 0.001, **P< 0.01, *P<0.05 lesion mephedrone compared to sham vehicle,
P<0.001, P<0.01, P<0.05 lesion mephedrone compared to lesion vehicle,
P<0.001, P<0.01, P<0.05 lesion mephedrone compared to sham mephedrone,
Bonferroni multiple comparisons post-hoc following four-way repeated measures ANOVA.
Fig. 3. Comparison of the effect of (a) the 5-HT1A receptor antagonist WAY-100635, (b) the
5-HT1B receptor antagonist GR 127935 and (c) the 5-HT7 receptor antagonist SB-258719 on
saline vehicle (1ml/kg) or mephedrone (10mg/kg)-induced change in locomotor activity
following a single injection in adult male Lister hooded rats (n=8 per treatment group).
Saline vehicle (1ml/kg), WAY-100635 (0.5mg/kg), GR 127935 (3mg/kg) or SB-258719
(10mg/kg) was injected -30 minutes, before saline or mephedrone at time = 0 min. All data
are presented as mean ± SEM Line indicates significance at indicated time points. *P<0.05,
***P<0.001 vehicle mephedrone versus vehicle vehicle; P<0.05, P<0.01, P<0.001
antagonist mephedrone versus vehicle vehicle; P<0.05, P<0.01, P<0.001 antagonist
mephedrone versus antagonist vehicle, P<0.05, P<0.05 antagonist mephedrone versus
vehicle mephedrone, Bonferroni post-hoc following three-way repeated measures ANOVA.
Fig. 4. Comparison of the effect of (a) the 5-HT1A receptor antagonist WAY-100635, (b) the
5-HT1B receptor antagonist GR 127935 and (c) the 5-HT7 receptor antagonist SB-258719 on
saline vehicle (1ml/kg) or mephedrone (10mg/kg) induced change in rectal temperature
following a single injection in adult male Lister hooded rats (n=8 per treatment group).
Saline vehicle (1ml/kg), WAY-100635 (0.5mg/kg), GR 127935 (3mg/kg) or SB-258719
(10mg/kg) were injected -30 minutes before saline or mephedrone at time = 0 min. Rectal
temperature was measured at -30 minutes and at 20 minute intervals from 0 to 120 minutes,
and data are expressed as change in temperature (°C, mean ± SEM) from the reading taken at
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0 minute. ***P<0.001 vehicle mephedrone versus vehicle vehicle; †P<0.05, †††P<0.001
antagonist mephedrone versus vehicle vehicle; †P<0.05, ††P<0.01, †††P<0.001 antagonist
mephedrone versus antagonist vehicle, Bonferroni post-hoc following three-way repeated
measures ANOVA.
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